U.S. markets closed
  • S&P 500

    4,473.75
    -6.95 (-0.16%)
     
  • Dow 30

    34,751.32
    -63.07 (-0.18%)
     
  • Nasdaq

    15,181.92
    +20.39 (+0.13%)
     
  • Russell 2000

    2,232.91
    -1.54 (-0.07%)
     
  • Crude Oil

    72.63
    +0.02 (+0.03%)
     
  • Gold

    1,752.90
    -3.80 (-0.22%)
     
  • Silver

    22.89
    +0.10 (+0.42%)
     
  • EUR/USD

    1.1769
    -0.0057 (-0.48%)
     
  • 10-Yr Bond

    1.3310
    +0.0270 (+2.07%)
     
  • GBP/USD

    1.3797
    -0.0039 (-0.28%)
     
  • USD/JPY

    109.7300
    +0.3700 (+0.34%)
     
  • BTC-USD

    47,589.36
    -556.98 (-1.16%)
     
  • CMC Crypto 200

    1,209.85
    -23.43 (-1.90%)
     
  • FTSE 100

    7,027.48
    +10.99 (+0.16%)
     
  • Nikkei 225

    30,323.34
    -188.37 (-0.62%)
     

Abbott Launches Latest Insertable Cardiac Monitor For Irregular Heart Rhythms

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Abbott Laboratories (NYSE: ABT) launched the Jot Dx, its latest insertable cardiac monitor (ICM), in the U.S.

  • The technology allows for remote detection and improved diagnostic accuracy of cardiac arrhythmias in patients.

  • Jot Dx offers clinicians and hospitals control of managing the flow of information through a feature that allows the viewing of abnormal heart rhythm data and provides the opportunity to simplify which irregular heart rhythms are recorded with a “key episodes” feature, according to a news release.

  • Data presented at Heart Rhythm 2021 demonstrated that Jot Dx provides a 63% data reduction burden.

  • Jot Dx ICM continuously monitors patient cardiac rhythms and connects directly to myMerlin, a downloadable mobile app that transmits real-time data to both the clinician and patient.

  • Price Action: ABT shares are down 0.12% at $121.24 during the market session on the last check Friday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.